Clinical Trials Browser

Phase 4 × venetoclax × Other hematologic neoplasm × Clear all

NCT07044687 2026-01-12

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

Phase 4 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05144243 2025-08-12

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

Phase 4 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06763666 2025-01-08

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Phase 4 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06571825 2024-08-26

RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

Phase 4 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04790045 2023-10-03

LymBIO

Phase 4 Not yet recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell